Dapirolizumab pegol improves SLE disease activity in phase III trial

IF 33.7 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2026-07-07 DOI:10.1038/s41584-026-01409-y

Sarah Onuora

引用次数: 0

Abstract

The results of a 48-week, randomized, placebo-controlled trial suggest that the novel CD40 ligand inhibitor dapirolizumab pegol could have clinical benefits for patients with systemic lupus erythematosus.

查看原文本刊更多论文

Dapirolizumab pegol III期临床试验改善SLE疾病活动性

一项为期48周的随机安慰剂对照试验结果表明，新型CD40配体抑制剂dapirolizumab pegol可能对系统性红斑狼疮患者具有临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.